Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04126057 · ClinicalTrials.gov registry record · NA

Myopia Assessment of Two Manufacturing Processes

A NA study of Juvenile Myopia, sponsored by SightGlass Vision.

Completed
Registry status
NA
Development phase
50
Enrollment target
5
Study locations

NCT04126057 is a NA study of Juvenile Myopia that has completed, run by SightGlass Vision. The registered enrollment target is 50 participants, below the 130-participant average among 6 other Juvenile Myopia trials with a reported enrollment target (62% lower). The trial reports 5 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04126057, a NA study of Juvenile Myopia, has completed, sponsored by SightGlass Vision.

COMPLETED
Registry status
NA
Development phase
50 participants
Enrollment target
5
Study locations

Study Summary

Randomized, controlled, multisite, subject- and observer-masked, contralateral clinical trial of 6-month duration to compare two SightGlass Vision Diffusion Optics Technology (DOT) spectacle lens manufacturing processes in reducing the progression of juvenile myopia.

Conditions Studied

Interventions

  • DEVICE SightGlass Vision DOT Spectacle Lenses

Study Locations (5)

Florida

  • Sabal Eye Care - Longwood

Kansas

  • Kannarr Eye Care - Pittsburg

Missouri

  • Advanced Eyecare PC - Raytown

New York

  • SUNY School of Optometry - New York

Utah

  • William J Bogus, OD, FAAO - Salt Lake City

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2019-12-02
Est. Completion 2020-09-16
Phase NA

Sponsor

SightGlass Vision

8 total trials

What the Registry Record Tells You About NCT04126057

The ClinicalTrials.gov registry entry for NCT04126057 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 130-participant average among 6 other Juvenile Myopia trials with a reported enrollment target (62% lower). The listed sponsor is SightGlass Vision, which has 8 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Juvenile Myopia appearing as the primary indexed condition, and to 1 intervention - of which SightGlass Vision DOT Spectacle Lenses is the first listed.

NCT04126057 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Florida, Kansas, Missouri.

Frequently Asked Questions

What is clinical trial NCT04126057 about?

NCT04126057 is a clinical study titled "Myopia Assessment of Two Manufacturing Processes". Randomized, controlled, multisite, subject- and observer-masked, contralateral clinical trial of 6-month duration to compare two SightGlass Vision Diffusion Optics Technology (DOT) spectacle lens manufacturing processes in reducing the progression of juvenile myopia.

What is the current status of trial NCT04126057?

This trial is currently completed. It is a NA study. The enrollment target is 50 participants. The study started on 2019-12-02. Estimated completion is 2020-09-16.

What conditions does trial NCT04126057 study?

This clinical trial studies the following conditions: Juvenile Myopia.

What interventions are being tested in trial NCT04126057?

The interventions under investigation include: SightGlass Vision DOT Spectacle Lenses (DEVICE).

Who is sponsoring clinical trial NCT04126057?

This trial is sponsored by SightGlass Vision, which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04126057 being conducted?

This trial has 5 study locations across Florida, Kansas, Missouri, New York, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Juvenile Myopia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.